AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12811566 — intervention group
Group type: EXPERIMENTAL
Intervention: IT(105%) - Intermittent training at 105% of vVO(2max)
Number of subjects: 7
Study 12811566 — intervention group
Group type: COMPARATOR
Intervention: Incremental test
Number of subjects: 7
Study 11153582 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuchamber (metal spacer) with Budesonide (200 microg b.i.d)
Number of subjects: 25
Study 11153582 — intervention group
Group type: EXPERIMENTAL
Intervention: nonDC-Babyhaler (detergent coated plastic spacer) with Fluticasone (125 microg b.i.d)
Number of subjects: 25
Study 11153582 — intervention group
Group type: EXPERIMENTAL
Intervention: DC-Babyhaler (non-detergent coated plastic spacer) with Fluticasone (125 microg b.i.d)
Number of subjects: 25
Study 9094151 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (2.4 g/day)
Number of subjects: 64
Study 9094151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 9094151 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide
Number of subjects: 64
Study 9094151 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical palliation
Number of subjects: 64
Study 9094151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor grade
Number of subjects: 64
Study 8249952 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (0.3 to 0.4 mg/kg)
Number of subjects: 10
Study 8249952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3510088 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 min of bicycling three times per week
Number of subjects: 12
Study 3510088 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 min of bicycling seven times per week
Number of subjects: 12
Study 3510088 — intervention group
Group type: COMPARATOR
Intervention: Below-sedentary activity
Number of subjects: 12
Study 3510088 — intervention group
Group type: COMPARATOR
Intervention: Sedentary activity
Number of subjects: 12
Study 31470735 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week online training program coupled with a physician engagement strategy
Number of subjects: 63
Study 31470735 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study 31470735 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week online training program
Number of subjects: 63
Study 30054920 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.9 mg/d
Number of subjects: 139
Study 30054920 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 50 mg/d
Number of subjects: 139
Study 30054920 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin 5 mg/d
Number of subjects: 139
Study 27299900 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 10
Study 27299900 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 10
Study 25223724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg twice daily for 52 weeks (group A)
Number of subjects: 918
Study 25223724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg twice daily for 4 weeks and then 150 mg once daily (group B)
Number of subjects: 918
Study 25223724 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks (group C)
Number of subjects: 918
Study 22396087 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation
Number of subjects: 50
Study 22396087 — intervention group
Group type: COMPARATOR
Intervention: Invalidation
Number of subjects: 50
Study 20200257 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/d of 80% CLA (50:50 cis-9,trans-11 and trans-10,cis-12 isomers)
Number of subjects: 62
Study 20200257 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/d of 80% CLA
Number of subjects: 62
Study 18519483 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with 32 mg of docosahexaenoic acid and 31 mg of arachidonic acid per 100 mL of human milk
Number of subjects: 141
Study 18519483 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 141
Study 18519483 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with docosahexaenoic acid and arachidonic acid
Number of subjects: 141
Study 16402647 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast, 10 mg
Number of subjects: 4924
Study 16402647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4924
Study 16402647 — intervention group
Group type: COMPARATOR
Intervention: Loratadine, 10 mg
Number of subjects: 4924
Study 12415411 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive 2-octylcyanoacrylate
Number of subjects: 59
Study 12415411 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular suture
Number of subjects: 59
Study 9892301 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 83
Study 9892301 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 83
Study 8896010 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural/general anesthesia (CEGA)
Number of subjects: 40
Study 8896010 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 40
Study 1758241 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (Sch) 1 mg/kg administered when T1 returned to 20% of control
Number of subjects: 40
Study 1758241 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (Sch) 1 mg/kg administered when T1 returned to 40% of control (Group II)
Number of subjects: 40
Study 1758241 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (Sch) 1 mg/kg administered when T1 returned to 60% of control (Group III)
Number of subjects: 40
Study 1758241 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (Sch) 1 mg/kg administered when T1 returned to 80% of control (Group IV)
Number of subjects: 40
Study 6177407 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-B
Number of subjects: 29
Study 6177407 — intervention group
Group type: COMPARATOR
Intervention: ACOMLA
Number of subjects: 29
Study 31872906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (atorvastatin)
Number of subjects: 66
Study 31872906 — intervention group
Group type: COMPARATOR
Intervention: Conventional statin therapy
Number of subjects: 66
Study 30616597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar plexus block
Number of subjects: 100
Study 30616597 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 100
Study 27804174 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily treatment for asthma and COPD
Number of subjects: 0
Study 27804174 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of multiple data sources
Number of subjects: 0
Study 26025795 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute hand massage
Number of subjects: 40
Study 26025795 — intervention group
Group type: COMPARATOR
Intervention: 15-minute hand-holding without massage (Control)
Number of subjects: 40
Study 24450370 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (MDT directional exercises for knee derangements and evidence-based exercises for nonresponders)
Number of subjects: 180
Study 24450370 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 180
Study 24450370 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 180
Study 22485049 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐TT
Number of subjects: 0
Study 22485049 — intervention group
Group type: COMPARATOR
Intervention: Control vaccines
Number of subjects: 0
Study 20848639 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Pulse (DP) mode
Number of subjects: 11
Study 20848639 — intervention group
Group type: COMPARATOR
Intervention: Standard Single Pulse (SSP) mode
Number of subjects: 11
Study 17931064 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation response (RR) tapes and soft music during acupuncture treatment; RR tapes listened to at home daily
Number of subjects: 80
Study 17931064 — intervention group
Group type: COMPARATOR
Intervention: Soft music during acupuncture treatment (control group)
Number of subjects: 80
Study 17931064 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation response (RR) tapes and soft music during acupuncture treatment
Number of subjects: 80
Study 16087945 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 U once weekly for 12 months
Number of subjects: 939
Study 16087945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 939
Study 12390569 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered amoxicillin at 500 mg, 3 times daily for 14 days
Number of subjects: 20
Study 12390569 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered metronidazole at 250 mg, 3 times daily for 14 days
Number of subjects: 20
Study 12390569 — intervention group
Group type: COMPARATOR
Intervention: SRP only or SRP followed by 14 days of orally administered doxycycline at 4 micro g/mL
Number of subjects: 20
Study 9824881 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Performance Task (CPT)
Number of subjects: 40
Study 9824881 — intervention group
Group type: EXPERIMENTAL
Intervention: Span of Apprehension Task (SPAN)
Number of subjects: 40
Study 9824881 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms assessment at 12 months
Number of subjects: 40
Study 7659739 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held dynamometer (myometer)
Number of subjects: 10
Study 7659739 — intervention group
Group type: EXPERIMENTAL
Intervention: Kin-Com dynamometer
Number of subjects: 10
Study 2649130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, with triiodothyronine)
Number of subjects: 222
Study 2649130 — intervention group
Group type: COMPARATOR
Intervention: Sequential single agent therapy (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, with vincristine)
Number of subjects: 222
Study 2649130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 222
Study 2649130 — intervention group
Group type: COMPARATOR
Intervention: Sequential single agent therapy
Number of subjects: 222
Study 7391628 — intervention group
Group type: EXPERIMENTAL
Intervention: A-Group: 900 mg of calcium, 50 mg of sodium fluoride, 50,000 units of vitamin D twice weekly
Number of subjects: 77
Study 7391628 — intervention group
Group type: EXPERIMENTAL
Intervention: B-Group: 900 mg of calcium, 50 mg of sodium fluoride
Number of subjects: 77
Study 7391628 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Group: 50 mg of sodium fluoride
Number of subjects: 77
Study 7391628 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Group: 900 mg of calcium, 50 mg of sodium fluoride, 2 mg of estriol
Number of subjects: 77
Study 7391628 — intervention group
Group type: EXPERIMENTAL
Intervention: E-Group: 2 mg of estriol
Number of subjects: 77
Study 7391628 — intervention group
Group type: EXPERIMENTAL
Intervention: F-Group: 900 mg of calcium
Number of subjects: 77
Study 7391628 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Group: 900 mg of calcium, 2 mg of estriol
Number of subjects: 77
Study 7391628 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 77
Study 30395006 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (penetrating needle at right Hegu acupoint LI-4)
Number of subjects: 0
Study 30395006 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (nonpenetrating needle)
Number of subjects: 0
Study 27928625 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (RT)
Number of subjects: 107
Study 26721134 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion treatment (14 sessions, based on Zusanli, Yinlingquan, Zhongwan, Danzhong, Neiguan, Taichong, Ganshu, Geshu, Danshu)
Number of subjects: 80
Study 26721134 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion treatment
Number of subjects: 80
Study 26721134 — intervention group
Group type: COMPARATOR
Intervention: Control group (Chinese herbs, one dose a day for 4 weeks)
Number of subjects: 80
Study 26721134 — intervention group
Group type: COMPARATOR
Intervention: Control group (Chinese herbs)
Number of subjects: 80
Study 22405557 — intervention group
Group type: EXPERIMENTAL
Intervention: One-dose-adjuvanted primary administration followed by a single-adjuvanted booster dose containing a heterologous vaccine strain
Number of subjects: 512
Study 22405557 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the interval between the first and second dose (from 21 days to 12 months)
Number of subjects: 512
Study 22405557 — intervention group
Group type: EXPERIMENTAL
Intervention: HI antibody response against the two strains
Number of subjects: 512
Study 22405557 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing antibody responses and CMI
Number of subjects: 512
Study 22405557 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall vaccine
Number of subjects: 512
Study 21236421 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro maturation treatment
Number of subjects: 128
Study 21236421 — intervention group
Group type: COMPARATOR
Intervention: Infertile control group
Number of subjects: 128
Study 19326598 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow ascent protocol (15 days to summit)
Number of subjects: 34
Study 19326598 — intervention group
Group type: COMPARATOR
Intervention: Fast ascent protocol (19 days to summit)
Number of subjects: 34
Study 17765775 — intervention group
Group type: EXPERIMENTAL
Intervention: Floseal (FS)
Number of subjects: 68
Study 17765775 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery (EC)
Number of subjects: 68
Study 16311300 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 50
Study 16311300 — intervention group
Group type: COMPARATOR
Intervention: DMPA alone
Number of subjects: 50
Study 14576538 — intervention group
Group type: EXPERIMENTAL
Intervention: 0% nitrous oxide with 1.2, 1.4, 1.6, 1.8, or 2.0% sevoflurane
Number of subjects: 120
Study 14576538 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% nitrous oxide with 0.8, 1.0, 1.2, 1.4, or 1.6% sevoflurane
Number of subjects: 120
Study 14576538 — intervention group
Group type: EXPERIMENTAL
Intervention: 67% nitrous oxide with 0.4, 0.6, 0.8, 1.0, or 1.2% sevoflurane
Number of subjects: 120
Study 10473995 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 830
Study 10473995 — intervention group
Group type: COMPARATOR
Intervention: Alfuzosin 2.5 mg three times daily
Number of subjects: 830
Study 10473995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 830
Study 8835055 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental zinc supplementation in daily dosages of 25‐100 mg po
Number of subjects: 0
Study 8835055 — intervention group
Group type: COMPARATOR
Intervention: Zinc supplementation
Number of subjects: 0
Study 1745854 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol 0.2 mg
Number of subjects: 12
Study 1745854 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol 1.0 mg
Number of subjects: 12
Study 1745854 — intervention group
Group type: COMPARATOR
Intervention: Oral salbutamol 4 mg
Number of subjects: 12
Study 1745854 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol 8 mg
Number of subjects: 12
Study 7049385 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose CMF
Number of subjects: 52
Study 7049385 — intervention group
Group type: COMPARATOR
Intervention: Low-dose CMF
Number of subjects: 52
Study 7049385 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CMF (both doses)
Number of subjects: 52
Study 29649341 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFlo® PICC (AngioDynamics Inc, Queensbury, NY)
Number of subjects: 150
Study 29649341 — intervention group
Group type: COMPARATOR
Intervention: Standard care (polyurethane PICC with a clamp)
Number of subjects: 150
Study 27100859 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time brief lifestyle consultation with a nurse (1 hour) and a nutritionist (1 hour) providing personalized lifestyle recommendations based on national guidelines.
Number of subjects: 126
Study 27100859 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the National Cancer Institute publication, 'Facing Forward: Life after Cancer Treatment.'
Number of subjects: 126
Study 25331236 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day regimen of oral ciprofloxacin (500mg, 12 hourly) and oral metronidazole (400mg, 8 hourly)
Number of subjects: 87
Study 25331236 — intervention group
Group type: COMPARATOR
Intervention: 5-day regimen of oral ciprofloxacin (500mg, 12 hourly) and oral metronidazole (400mg, 8 hourly)
Number of subjects: 87
Study 22535748 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 25
Study 20685495 — intervention group
Group type: EXPERIMENTAL
Intervention: OLM/AZL 20/16 mg
Number of subjects: 862
Study 20685495 — intervention group
Group type: EXPERIMENTAL
Intervention: OLM/AZL 10/8 mg
Number of subjects: 862
Study 20685495 — intervention group
Group type: COMPARATOR
Intervention: OLM
Number of subjects: 862
Study 20685495 — intervention group
Group type: COMPARATOR
Intervention: AZL
Number of subjects: 862
Study 18164463 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive nuclear decompression
Number of subjects: 0
Study 18164463 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical therapies
Number of subjects: 0
Study 16503317 — intervention group
Group type: EXPERIMENTAL
Intervention: EZE + statin
Number of subjects: 1307
Study 16503317 — intervention group
Group type: COMPARATOR
Intervention: Placebo + statin
Number of subjects: 1307
Study 12094185 — intervention group
Group type: EXPERIMENTAL
Intervention: High diuretic doses
Number of subjects: 1153
Study 12094185 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of metolazone
Number of subjects: 1153
Study 12094185 — intervention group
Group type: EXPERIMENTAL
Intervention: Low angiotensin-converting enzyme inhibitor dose
Number of subjects: 1153
Study 10333344 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (12-15 g NaCl/day)
Number of subjects: 53
Study 10333344 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (1-3 g NaCl/day)
Number of subjects: 53
Study 8618187 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose schedule at 1 and 3 months
Number of subjects: 196
Study 8618187 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose schedule at 2 and 4 months
Number of subjects: 196
Study 8618187 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose schedule at 2 and 6 months
Number of subjects: 196
Study 8618187 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose schedule at 4 and 6 months
Number of subjects: 196
Study 8618187 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dose schedule at 2, 4, and 6 months
Number of subjects: 196
Study 8618187 — intervention group
Group type: EXPERIMENTAL
Intervention: All schedules
Number of subjects: 196
Study 1941708 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered DIS (S-DISSI)
Number of subjects: 0
Study 1941708 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer-administered DIS (I-DISSI)
Number of subjects: 0
Study 1941708 — intervention group
Group type: COMPARATOR
Intervention: Traditional interviewer-administered DIS (T-DIS)
Number of subjects: 0
Study 7102384 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 53
Study 7102384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 31483891 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus
Number of subjects: 75
Study 31483891 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids
Number of subjects: 75
Study 29629619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (oral formulations)
Number of subjects: 28
Study 28623823 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200mg twice daily
Number of subjects: 302
Study 28623823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 25855851 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical platelet derived growth factor (Regranex)
Number of subjects: 46
Study 25855851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 23339536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 395
Study 23339536 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Supportive Psychotherapy (BSP)
Number of subjects: 395
Study 21226820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day
Number of subjects: 36
Study 20205019 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive condition (n = 80)
Number of subjects: 166
Study 20205019 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 86)
Number of subjects: 166
Study 16824248 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol medium‐chain triglyceride/long‐chain triglyceride + lidocaine
Number of subjects: 464
Study 16824248 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol long‐chain triglyceride + lidocaine
Number of subjects: 464
Study 16824248 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol medium‐chain triglyceride/long‐chain triglyceride
Number of subjects: 464
Study 16824248 — intervention group
Group type: COMPARATOR
Intervention: propofol long‐chain triglyceride
Number of subjects: 464
Study 12959823 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based (CB) recruitment strategies
Number of subjects: 833
Study 12959823 — intervention group
Group type: COMPARATOR
Intervention: Clinic centre site-visit (CSV) recruitment
Number of subjects: 833
Study 12959823 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based (CB) recruitment
Number of subjects: 833
Study 10636276 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoue technique
Number of subjects: 302
Study 10636276 — intervention group
Group type: COMPARATOR
Intervention: double-balloon technique
Number of subjects: 302
Study 8956632 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol (0.5%)
Number of subjects: 15
Study 8956632 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical latanoprost (0.005%)
Number of subjects: 15